Novo Nordisk downgraded by leading banks as CagriSema trial flops against Zepbound

Novo Nordisk downgraded by leading banks as CagriSema trial flops against Zepbound Proactive uses images sourced from Shutterstock The failure of its next-generation obesity drug to match Eli Lilly's blockbuster has blown a hole in Novo's post-Ozempic strategy, with analysts slashing price targets and two major banks walking away from bullish positions Novo Nordisk's (NYSE:NVO) last best hope for life after semaglutide has stumbled badly. The Danish drugmaker's CagriSema combination jab failed on Monday to ...